<?xml version="1.0" encoding="UTF-8"?>
<ref id="B130">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Modjarrad</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>George</surname>
    <given-names>S. L.</given-names>
   </name>
   <name>
    <surname>Stephenson</surname>
    <given-names>K. E.</given-names>
   </name>
   <name>
    <surname>Eckels</surname>
    <given-names>K. H.</given-names>
   </name>
   <name>
    <surname>De La Barrera</surname>
    <given-names>R. A.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2018</year>). 
  <article-title>Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.</article-title>
  <source>
   <italic>Lancet</italic>
  </source>
  <volume>391</volume>
  <fpage>563</fpage>â€“
  <lpage>571</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33106-9</pub-id>
  <?supplied-pmid 29217375?>
  <pub-id pub-id-type="pmid">29217375</pub-id>
 </mixed-citation>
</ref>
